Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from William Blair

Why Is Sanofi Stock Falling Thursday?

On Thursday, Sanofi SA (NASDAQ:SNY) stock tumbled after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fresh doubts about the company’s ability to sustain its dermatology franchise once patent protections expire.

Telix Gets Second FDA Rejection For Kidney Cancer Drug

Telix Gets Second FDA Rejection For Kidney Cancer Drug

On Thursday, Telix Pharmaceuticals Limited (NASDAQ:TLX) received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for TLX250-CDx (Zircaix, 89Zr-DFO girentuximab), an investigational PET2 agent for the diagnosis and characterization of renal masses as clear cell renal cell carcinoma (ccRCC).

Lung Disease-Focused Insmed 'Must-Own' Name For Investors

Lung Disease-Focused Insmed 'Must-Own' Name For Investors

William Blair initiated coverage on Insmed Incorporated (NASDAQ:INSM), citing that the clinical and commercial execution of its drugs can significantly increase Insmed's valuation.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction

In a stunning reversal, Dr. Vinay Prasad is returning to his role as director of the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER), just days after his resignation.

Exact Sciences Dip A Chance To Buy As Freenome Deal Fortifies Future: Analyst

Exact Sciences Corp. (NYSE:EXAS) on Thursday reported a second-quarter 2025 EPS loss of 1 cent, up from a 9-cent loss a year ago, beating the analyst consensus loss estimate of 19 cents.

Elanco Animal Health Soars Past 52-Week High On Strong Sales, Raised Annual Outlook

Elanco Animal Health Incorporated (NYSE:ELAN) reported second-quarter 2025 results on Thursday, posting adjusted earnings per share of 26 cents, down 13% year over year.

Weakness In Vertex Stock Seen As Buying Opportunity

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) stock is falling on Tuesday after the company’s pain data overshadowed strong second-quarter earnings.

inkl

Read news from The Economist, FT, and more,
with one subscription

BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030

BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030

On Tuesday, Biomarin Pharmaceutical Inc. (NASDAQ:BMRN) reported second-quarter adjusted earnings of $1.44, up 50% year over year, beating the consensus of 85 cents and sales of $825.41 million, up 16%, beating the consensus of $760.39 million.

Zoetis Lifts Outlook As Companion Animal Portfolio Offsets Librela Decline

Zoetis Lifts Outlook As Companion Animal Portfolio Offsets Librela Decline

Animal health firm Zoetis Inc. (NYSE:ZTS) on Tuesday reported a second-quarter 2025 adjusted earnings per share of $1.76, up from $1.56 a year ago, beating the consensus of $1.61.

Sephience Gets FDA Approval, Now A Key Revenue Driver For PTC Therapeutics

Sephience Gets FDA Approval, Now A Key Revenue Driver For PTC Therapeutics

The U.S. Food and Drug Administration approved on Monday PTC Therapeutics, Inc.’s (NASDAQ:PTCT) SEPHIENCE (sepiapterin) for children and adult patients with phenylketonuria (PKU).

Analyst Surprised By Exelixis Q2 Revenue Miss, Delays STELLAR-304 Readout, Halts STELLAR-305 Phase 3 Plans

Analyst Surprised By Exelixis Q2 Revenue Miss, Delays STELLAR-304 Readout, Halts STELLAR-305 Phase 3 Plans

Exelixis Inc. (NASDAQ:EXEL) on Monday reported its first quarter of 2025 adjusted earnings of 75 cents per share, compared to 85 cents a year ago, beating the consensus of 56 cents.

FDA Approval For Empaveli Marks Key Milestone In Apellis' Rare Disease Portfolio

FDA Approval For Empaveli Marks Key Milestone In Apellis' Rare Disease Portfolio

The U.S. Food and Drug Administration approved on Monday Apellis Pharmaceuticals, Inc.’s (NASDAQ:APLS) Empaveli (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, to reduce proteinuria.

Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand

Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand

Incyte Corporation (NASDAQ:INCY) reported on Tuesday that its second-quarter revenue was $1.22 billion, up 16% year over year. The company beat the consensus of $1.15 billion.

Tesla Just Signed a Chip Supply Deal with Samsung. What Does That Mean for TSLA Stock?

Tesla Just Signed a Chip Supply Deal with Samsung. What Does That Mean for TSLA Stock?

Tesla stock inches up as the EV maker announces a $16.5 billion deal with Samsung Electronics. William Blair still remains dovish on TSLA shares for the second half of 2025.

Get all your
news in one place.

100’s of premium titles.
One news app.

ICON Stock Up After Q2 Results Signal Growing Confidence In Biopharma Recovery

Clinical research organization ICON plc (NASDAQ:ICLR) stock is surging on Thursday after the company reported better-than-expected second-quarter financial results and raised its fiscal 2025 sales guidance.

Sarepta Reverses Course, Pauses Elevidys Shipments Amid FDA Safety Review

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced Monday it will voluntarily and temporarily pause all U.S. shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, effective July 22.

Sarepta Faces Regulatory Showdown As Analysts Cut Price Targets

On Friday, the U.S. Food and Drug Administration placed Sarepta Therapeutics Inc.’s (NASDAQ:SRPT) investigational gene therapy clinical trials for limb girdle muscular dystrophy (LGMD) on a clinical hold.

Sarepta Therapeutics' Reorganization Boosts Investor Confidence

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock is trading higher on Thursday after the company issued an after-hours update on ongoing label expansion efforts for Elevidys, its approved gene therapy for Duchenne muscular dystrophy.

Get all your
news in one place.

100’s of premium titles.
One news app.

Is Palantir Stock a Buy, Sell, or Hold on New Nuclear Deal?

Palantir stock remains in focus as the big data analytics firm teamed up with The Nuclear Company. William Blair recommends caution in buying PLTR shares.

QuantumScape Just Announced a Major Cobra Milestone. How Should You Play QS Stock Here?

QuantumScape stock soars on successful integration of Cobra separator process into baseline cell production. William Blair recommends selling QS shares before they fade again.

Palantir Is Reportedly Building a US ‘Spy Machine.’ How Should You Play PLTR Stock Here?

Palantir is reportedly building a “spy machine” for the Trump administration. William Blair remains bearish on PLTR shares for the remainder of 2025.

Legal tech startup ProfitSolv seeks buyer amid sluggish merger climate

Bankers don’t expect “Trump Bump” will boost mergers this year

Palantir Stock Gets Upgrade: Is it Time to Buy PLTR After Recent Slump?

Leading broker William Blair, an erstwhile cynic has recently upgraded the stock.

Investors Business Daily

DeepSeek Upended Wall Street's Rosy View Of AI Stocks Like Nvidia. What That Means For U.S. Hopes To Outrun China.

While AI stocks may rebound from their DeepSeek-induced market sell-off, the U.S. clearly faces a threat from China in artificial intelligence. What you should know.

Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says

Axsome's AXS-12 met Phase 3 trial goals, cutting cataplexy attacks by 77% over six months and improving cognition with a favorable safety profile.

People

138,944 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

302,736 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play